The Outcome of Neutralizing Monoclonal Antibodies versus Favipiravir Treatment among Mild to Moderate COVID-19 in Middle-aged Patients and Special Populations in Outpatient Clinic

Chulabhorn Royal Academy0 个研究点目标入组 1,410 人开始时间: 2023年9月12日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Confirmed SARS-COV-2 infected cases by Reverse Transcriptase-Polymerase Chain Reaction or antigen test kit who were treated with outpatients, home isolation 2. Mild to moderate COVID-19 in those aged 40-60, elderly, diabetes mellitus, and obesity 3. Participants accept informed consent 4. body weight more than 40 kilograms
•5. Asymptomatic or Symptomatic by present more than or equal to one of the following symptoms: fever, runny nose, sore throat, cough, myalgia, diarrhea, chest discomfort, dyspnea
•6. Chest CT severity score 0-14
•7. WHO clinical progression scale < 2
•8. Age more than 18 years

•1) Respiratory tract symptoms compatible with a bacterial infection 2) Previous receiving anti-SARS-CoV-2 agents more than 24 hours
•3) severe COVID-19 or signs and symptoms deterioration at the first visit; respiratory rate more than 26, oxygen saturation less than 95, hypotension defined by SBP less than 90 and DBP less than 60
•4.) Need oxygen therapy
•5) Pregnancy or breastfeeding
•6) Who needs an increased flow of oxygen supplemental in chronic respiratory illnesses
•7) Who needs hospitalization for any cause
•8) Chest X-ray presents bilateral infiltration or infiltration more than 50 percent or CT chest presence crazy paving pattern or ARDS pattern or CT severity score more than 15
•9) Cirrhosis child C or end-stage renal disease who did not receive hemodialysis more than 2 times a week
•10) Advanced malignancy (life expectancy less than 3 months)
•11) Bedridden
•12) who received neutralizing monoclonal antibodies for more than 60 days
•13) Casirivimab imdevimab, sotrovimab or favipiravir

发起方